Adaptimmune Therapeutics PLC Stock Ownership - Who owns Adaptimmune Therapeutics?

Insider buying vs selling

Have Adaptimmune Therapeutics PLC insiders been buying or selling?
John LungerChief Patient Supply Officer2024-01-1712,805$0.67
Elliot NorryChief Medical Officer2024-01-175,309$0.67
Elliot NorryChief Medical Officer2024-01-1712,967$0.67
William C. Bertrand Jr.Chief Operating Officer2024-01-1713,599$0.67
William C. Bertrand Jr.Chief Operating Officer2024-01-175,309$0.67
Adrian RawcliffeChief Executive Officer2024-01-1730,080$0.67
John LungerChief Patient Supply Officer2024-01-175,309$0.67
Elliot NorryChief Medical Officer2024-01-162,287$0.79
John LungerChief Patient Supply Officer2024-01-164,681$0.79
Adrian RawcliffeChief Executive Officer2024-01-169,304$0.79

1 of 3

ADAP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ADAP insiders and whales buy or sell their stock.

ADAP Shareholders

What type of owners hold Adaptimmune Therapeutics PLC stock?
David M. Mott11.87%161,747,668$223.21MInsider
Peter W. Sonsini11.87%161,747,668$223.21MInsider
Forest Baskett11.87%161,747,668$223.21MInsider
Scott D. Sandell11.87%161,747,668$223.21MInsider
Anthony A. Florence Jr.11.87%161,747,668$223.21MInsider
Ravi Viswanathan11.32%154,247,668$212.86MInsider
Peter J. Barris11.32%154,247,668$212.86MInsider
M. James Barrett10.44%142,247,668$196.30MInsider
Patrick J. Kerins10.44%142,247,668$196.30MInsider
New Enterprise Associates 14 LP6.09%82,978,668$114.51MInsider

1 of 3

ADAP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ADAP7.94%92.06%Net SellingNet Selling
AURA81.45%18.55%Net BuyingNet Selling
PEPG68.04%21.22%Net BuyingNet Buying
EPIX73.10%26.90%Net BuyingNet Buying
ENGN23.75%50.51%Net BuyingNet Buying

Adaptimmune Therapeutics Stock Ownership FAQ

Who owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics (NASDAQ: ADAP) is owned by 10.54% institutional shareholders, 122.14% Adaptimmune Therapeutics insiders, and 0.00% retail investors. David M. Mott is the largest individual Adaptimmune Therapeutics shareholder, owning 161.75M shares representing 11.87% of the company. David M. Mott's Adaptimmune Therapeutics shares are currently valued at $239.39M.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.